Swahili
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Transperineal Laser Ablation for Treatment of Benign Prostatic Obstruction

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
Kiungo kimehifadhiwa kwenye clipboard
HaliKuajiri
Wadhamini
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Washirika
Elesta S.R.L.

Maneno muhimu

Kikemikali

Rationale: With age a large group of men experience lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO). Standard treatment is a transurethral resection of the prostate or laser vaporization. As these techniques enter the prostate via the urethra, are invasive and require general or spinal anaesthesia. Transperineal laser ablation (TPLA) is a minimal invasive procedure, that can be performed under local anaesthesia.
Objective: The primary objective of this study is to prove feasibility and safety of TPLA for LUTS due to BPO in healthy men.
Secondary objectives: The secondary objectives are to determine functional voiding, erectile outcomes and changes on imaging.

Maelezo

This study is set up as a prospective, single centre, interventional pilot study.

Eligible patients are diagnosed with LUTS due to BPO at the outpatient clinic of the department of Urology at the Academic Medical Center (AMC) and have an indication for surgical treatment. The investigators aim to include 20 patients.

Eligible patients will be informed about this study by the urologist in the outpatient clinic. Information about the study will be provided both orally and in written form.

The TPLA procedure is performed with the Echolaser X4 system. The system uses a diode laser source that operates at the 1064nm wavelength. The maximum energy delivered is 10 watts per laser source. The system works with the concept of thermoablation, resulting in coagulative necrosis of tissue. Two to four fibers are introduced in the prostate under untrasound vision. Ablation will be performed with 3 watts power per fibre and a total of 1200 - 1800 J will be delivered per fibre in 400 - 600 s.

Follow-up will exist of four visits following surgery at 4 weeks, three, six and 12 months. The visits imply medical history, adverse event registration, physical examination (on indication) and uroflowmetry. Patient-reported outcome measures (PROMs) are used to measure functional outcomes. Used PROMs are the International Prostate Symptom Score (IPSS), International Index of Erectile Function 15 (IIEF-15), Visual Analogue Scale (VAS) and hematuria grading scale (HGS). In addition to this, imaging will exist of a contrast enhanced ultrasound (CEUS) at four weeks and 12 months.

Tarehe

Imethibitishwa Mwisho: 12/31/2018
Iliyowasilishwa Kwanza: 08/21/2018
Uandikishaji uliokadiriwa Uliwasilishwa: 08/27/2018
Iliyotumwa Kwanza: 08/30/2018
Sasisho la Mwisho Liliwasilishwa: 01/17/2019
Sasisho la Mwisho Lilichapishwa: 01/21/2019
Tarehe halisi ya kuanza kwa masomo: 10/17/2018
Tarehe ya Kukamilisha Msingi iliyokadiriwa: 06/30/2019
Tarehe ya Kukamilisha Utafiti: 06/30/2020

Hali au ugonjwa

Prostatic Hyperplasia, Benign

Uingiliaji / matibabu

Device: TPLA

Awamu

-

Vikundi vya Arm

MkonoUingiliaji / matibabu
Experimental: TPLA
TPLA procedure
Device: TPLA
Minimal invasive coagulation of prostatic tissue by laser

Vigezo vya Kustahiki

Zama zinazostahiki Kujifunza 40 Years Kwa 40 Years
Jinsia Inastahiki KujifunzaMale
Hupokea Wajitolea wa AfyaNdio
Vigezo

Inclusion Criteria:

- Male

- ≥ 40 years of age

- Peak urinary flow rate (Qmax): ≥ 5 mL/sec to ≤ 15 mL/sec, with a minimum voided volume of ≥ 125 mL, measured with uroflowmetry or urodynamic investigation

- Post-void residual (PVR): ≤ 250 mL

- Prostate volume: ≥ 30 and ≤ 120 cc, measured by transrectal ultrasound

- Urodynamic investigation proven bladder outlet obstruction

- Signed informed consent

Exclusion Criteria:

- Previous invasive prostate intervention (TURP, laser, ablation, etc.)

- History of prostate or bladder cancer

- Indwelling Foley catheter or clean intermittent catheterization (CIC)

- PSA of ≥ 3.0 ng/mL without negative biopsies

- Inability or unwillingness to tolerate temporary discontinuation of anticoagulation or anti-platelet therapy

- Other conditions / status

- Active urinary tract infection / prostatitis

- Macroscopic haematuria without a known contributing factor

- Poor detrusor muscle function or other neurological disorder that would impact bladder function (eg, multiple sclerosis, Parkinson's disease, spinal cord injuries, (diabetic) polyneuropathy)

- Concurrent malignancy except basal skin cancer

- History of lower urinary tract surgery (eg, TURP, laser, urinary diversion, artificial urinary sphincter, penile prosthesis)

- History of pelvic radiation therapy or radical pelvic surgery

- History of bladder neck contracture and/or urethral strictures within the 5 years prior to the informed consent date

- Bladder stones

- Medical contraindication for undergoing TPLA surgery (eg, infection, coagulopathy, significant cardiac or other medical risk factors for surgery)

- Diagnosed or suspected bleeding disorder

Matokeo

Hatua za Matokeo ya Msingi

1. Incidence of technical successful TPLA treatments [24 hours following TPLA treatment]

Number of technical successful performed TPLA treatments without failures related to the machine or procedure.

2. Incidence of TPLA treatment-emergent adverse events [30 days following TPLA treatment]

Number of adverse events using the CTCAE v5.0. Procedural safety is shown when there are no adverse events of grade 3 or higher.

Hatua za Matokeo ya Sekondari

1. Functional outcomes of TPLA [12 months following TPLA treatment]

Functional outcomes of TPLA measured by uroflowmetry, expressed in change of Qmax.

2. Spontaneous voiding post TPLA [24 hours following TPLA treatment]

The presence of spontaneous voiding following TPLA treatment

3. Erectile function [12 months following TPLA treatment]

To evaluate erectile function after TPLA treatment, measured by the International Index of Erectile function 15 (IIEF-15) IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; Erectile function: Q1-5 Score range 0-5 + Q15 score range 1-5, total score 1-30, higher indicates better outcome; Orgasmic function: Q9-10 Score range 0-5, total score 0-10, higher indicates better outcome; Sexual desire: Q11-12 Score range 1-5, total score 2-10, higher indicates better outcome; Intercourse satisfaction: Q6-8 Score range 0-5, total score 0-15, higher indicates better outcome; Overall satisfaction: Q13-14 Score range 1-5, total score 2-10, higher indicates better outcome; All subscale are summed to combine them to a total IIEF-15 score.

4. Antegrade ejaculation [12 months following TPLA treatment]

To evaluate antegrade ejaculation after TPLA treatment, measured by patient reporting.

Jiunge na ukurasa
wetu wa facebook

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi

  • Inafanya kazi katika lugha 55
  • Uponyaji wa mitishamba unaungwa mkono na sayansi
  • Kutambua mimea kwa picha
  • Ramani ya GPS inayoshirikiana
  • Soma machapisho ya kisayansi yanayohusiana na utafutaji wako
  • Tafuta mimea ya dawa na athari zao
  • Panga maslahi yako na fanya tarehe ya utafiti wa habari, majaribio ya kliniki na ruhusu

Andika dalili au ugonjwa na usome juu ya mimea ambayo inaweza kusaidia, chapa mimea na uone magonjwa na dalili ambazo hutumiwa dhidi yake.
* Habari zote zinategemea utafiti wa kisayansi uliochapishwa

Google Play badgeApp Store badge